echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Ann Oncol: Large-scale prospective GWAS identification of single nucleotide polymorphisms (SNPs) predicting oxaliplatin-mediated peripheral sensory neuropathy (PSN)

    Ann Oncol: Large-scale prospective GWAS identification of single nucleotide polymorphisms (SNPs) predicting oxaliplatin-mediated peripheral sensory neuropathy (PSN)

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Oxaliplatin (L-OHP) is a third-generation platinum compound and a commonly used chemotherapy drug for colorectal cancer


    Oxaliplatin (L-OHP) is a third-generation platinum compound and a commonly used chemotherapy drug for colorectal cancer


    The prospective GWAS study included 1379 patients with stage II/III colon cancer who received L-OHP-based (mFOLFOX6/CAPOX) adjuvant chemotherapy in a phase II (JOIN/JFMC41) or phase III (ACHIVE/JFMC47) trial


    The prospective GWAS study included 1379 patients with stage II/III colon cancer who received L-OHP-based (mFOLFOX6/CAPOX) adjuvant chemotherapy in a phase II (JOIN/JFMC41) or phase III (ACHIVE/JFMC47) trial



     Clinical features

    Among the 1379 patients included in the GWAS analysis, the data of 1364 patients were analyzed


    Among the 1379 patients included in the GWAS analysis, the data of 1364 patients were analyzed


    The researchers then explored related SNPs that can predict the recovery time of PSN


    The researchers then explored related SNPs that can predict the recovery time of PSN


    The researchers then explored related SNPs that can predict oxaliplatin-mediated allergic reactions (AR)


    The researchers then explored related SNPs that can predict oxaliplatin-mediated allergic reactions (AR)


    Finally, GWAS explores related SNPs that can predict disease recurrence


    In summary, the study failed to find meaningful SNPs that can predict oxaliplatin-mediated PSN, and there are greater clinical challenges in follow-up


    Original source:

    Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A , Yoshino T, Saji S, Matsuda F.


    Kanai M, Kawaguchi T, Kotaka M, Manaka D, Hasegawa J, Takagane A, Munemoto Y, Kato T, Eto T, Touyama T, Matsui T, Shinozaki K, Matsumoto S, Mizushima T, Mori M, Sakamoto J, Ohtsu A , Yoshino T, Saji S, Matsuda F.
    Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy.
    Ann Oncol.
    2021 Nov;32(11):1434-1441.
    doi: 10.
    1016/ j.
    annonc.
    2021.
    08.
    1745.
    Epub 2021 Aug 12.
    PMID: 34391895.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.